STOCK TITAN

Viridian Therapeutics Inc SEC Filings

VRDN NASDAQ

Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading a biotech filing often feels like decoding a medical journal, and Viridian Therapeutics’ reports are no exception. Clinical trial timelines, antibody engineering details, and cash-runway disclosures can hide across hundreds of pages. If you have ever searched, “How do I find Viridian Therapeutics’ quarterly earnings report 10-Q filing?” you already know the challenge.

Stock Titan’s AI-powered summaries turn those dense sections into plain-English insights. Open a 10-K and our platform immediately flags R&D expense trends, notes on IGF-1R antibody progress, and risk factors unique to thyroid eye disease. Need real-time alerts? We post every Viridian Therapeutics 8-K material events explained within minutes of hitting EDGAR—whether it is a phase-2 data release or a new licensing deal. For governance watchers, the proxy statement executive compensation breakdown highlights how leadership incentives align with clinical milestones.

Tracking ownership shifts is just as simple. Our dashboard lists Viridian Therapeutics insider trading Form 4 transactions alongside AI context, so you see why an executive bought or sold shares. Prefer live updates? Activate “Viridian Therapeutics Form 4 insider transactions real-time” alerts before market open. Quarterly comparisons are equally clear: the latest “Viridian Therapeutics earnings report filing analysis” shows burn-rate changes at a glance, while the “Viridian Therapeutics annual report 10-K simplified” section connects cash needs to upcoming TED trial costs.

From understanding Viridian Therapeutics SEC documents with AI to locating a single line item on deferred tax assets, every filing type—10-Q, 10-K, 8-K, S-3, or DEF 14A—is indexed, summarized, and linked. Save hours, spot pivotal disclosures early, and act with confidence.

Rhea-AI Summary

JPMorgan Chase Financial Company LLC has filed a Rule 424(b)(2) pricing supplement for $7.007 million of Auto-Callable Contingent Interest Notes linked to Alphabet Inc. (GOOGL) Class A common stock, fully and unconditionally guaranteed by JPMorgan Chase & Co. The notes price on 26 June 2025, settle on or about 1 July 2025 and mature on 31 December 2026 unless called earlier.

Key structural terms

  • Denomination: $1,000 (CUSIP 48136EQ73)
  • Initial Value (GOOGL close 26 Jun 2025): $173.54
  • Interest Barrier / Trigger Value: 64 % of Initial Value ($111.0656)
  • Contingent Interest: 10.00 % p.a. (2.50 % quarterly) with a “memory” feature; payable only if the reference stock closes ≥ Interest Barrier on a Review Date.
  • Automatic Call: If GOOGL closes ≥ Initial Value on any Review Date other than the final date, investors receive $1,000 plus all due coupons and the notes terminate early.
  • Principal at Risk: If not called and Final Value < Trigger, repayment = $1,000 + ($1,000 × Stock Return). Investors lose 1 % of principal for every 1 % decline below Initial Value, exposing them to loss of >36 % and up to 100 %.
  • Review / Payment schedule: Sept 26 2025, Dec 26 2025, Mar 26 2026, Jun 26 2026, Sept 28 2026, Dec 28 2026 (final); coupons paid five days later or at maturity.

Pricing economics

  • Price to public: $1,000; Selling commissions: $15 (1.50 %); Net proceeds: $985.
  • Estimated value at pricing: $978.50 (≈ 97.85 % of face), reflecting internal funding rate, hedging costs and dealer margin—highlighting a 2.15 % premium paid by investors.

Illustrative payouts

  • If automatically called at first Review Date with GOOGL ≥ $173.54, total return = 2.5 %.
  • If held to maturity with GOOGL ≥ Trigger and no call, maximum total coupon income = $150 (15 % over 18 months).
  • If Final Value is 54 % of Initial (below Trigger), investor receives $540 (–46 % total return).

Principal risks

  • Principal and coupon risk: No principal protection; coupons contingent.
  • Credit risk: Payments depend on JPMorgan Financial and JPMorgan Chase & Co.
  • Limited upside: Return capped at cumulative coupons; no participation in GOOGL appreciation.
  • Liquidity: No exchange listing; secondary price set by JPMS and may be well below issue price.
  • Valuation gap: Issue price exceeds estimated value by $21.50 per note.
  • Tax: Issuer intends to treat notes as prepaid forward contracts with ordinary-income contingent coupons; tax treatment uncertain for both U.S. and non-U.S. holders.

The filing provides extensive risk disclosures, historical GOOGL price data, hypothetical scenarios and legal opinions, enabling investors to evaluate the structured note’s risk-return profile relative to direct equity or fixed-income alternatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Viridian Therapeutics (VRDN)?

The current stock price of Viridian Therapeutics (VRDN) is $14.33 as of June 28, 2025.

What is the market cap of Viridian Therapeutics (VRDN)?

The market cap of Viridian Therapeutics (VRDN) is approximately 1.2B.

What is the primary focus of Viridian Therapeutics Inc?

Viridian Therapeutics Inc is primarily focused on developing innovative therapies for thyroid eye disease through advanced monoclonal antibody technology targeting the IGF-1R pathway.

What is Veligrotug and how is it administered?

Veligrotug is a humanized monoclonal antibody product candidate developed by Viridian Therapeutics Inc. It is designed for intravenous administration, offering a targeted approach to modifying disease progression in thyroid eye disease.

How does the company differentiate its therapeutic approach?

The company differentiates its approach by integrating advanced antibody engineering with dual administration modalities, which enhances treatment flexibility and aligns with the specific clinical needs associated with thyroid eye disease.

What role does IGF-1R play in the company’s product development?

IGF-1R is the molecular target for Viridian Therapeutics Inc's key therapeutic candidate. By focusing on this receptor, the company aims to modulate critical biological pathways involved in the inflammatory process of thyroid eye disease.

How does Viridian Therapeutics Inc position itself within the biotech industry?

By specializing in a well-defined market segment with significant unmet medical need, the company positions itself as an expert in the niche field of thyroid eye disease through precise targeting of disease-relevant pathways and rigorous clinical research.

Does the company engage in strategic collaborations?

Yes, Viridian Therapeutics Inc enhances its research capabilities through strategic collaborations and partnerships within the scientific and biotech communities, further solidifying its expertise and operational credibility.
Viridian Therapeutics Inc

NASDAQ:VRDN

VRDN Rankings

VRDN Stock Data

1.20B
80.80M
0.12%
114.02%
11.74%
Biotechnology
Services-medical Laboratories
Link
United States
WALTHAM